M.P. Brizzi

Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort

M. Davi’, M. Zatelli, F. Gelsomino, 2024, Journal of clinical medicine.

A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas.

L. Antonuzzo, F. Recine, F. Gelsomino, 2024, European journal of cancer.

Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives

A. La Salvia, M. Cives, G. Lamberti, 2023, Journal of clinical medicine.

Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial

L. Porcu, M. Milione, F. de Braud, 2023, BMC Cancer.